Novel spectacle lens design for Myopia

Most of the myopic children have high myopia onset in their adult lifetime. In most of them, the main cause was near work or high near work environment.

Myopia is treated with various combinations of refractive lenses, atropine, a posterior segment block, a peribulbar block, and/or soft contact lenses. While these therapies have proven valuable in eliminating symptoms and preventing vision loss, more research is needed to determine optimal dosing (amounts and amounts over which the individual is comfortable). Eye surgery is only recommended for those patients who are not better off with the other treatments.

It is possible for myopia to develop in children. It is common for children with signs of myopia to have parents who have myopia. It is also possible for a child who has myopia to develop signs.

The prevalence of myopia in the community varies greatly worldwide. Myopia is an asymptomatic and treatable condition affecting approximately 1.3% of the world's eye population. The first systematic work on refractive errors started with Thomas Young and his work with ocular refractive errors in the 19th century.\n

Myopia seems to be a complex genetic trait. In addition to the major myopia-causing genes, we identified another myopia locus in 1p36 and a number of other loci with significant linkage at the genome-wide significance level. The linkage between two candidate genes in region 1p36 underscores the importance of genetic factors in myopia.

There is no evidence to suggest that myopia can be cured. Rather patients must be taught and encouraged to wear contact lenses as appropriate as they develop presbyopia and keratoconus, and they must be warned that contact lens wear may increase their risk of further refractive error.

Nearly 20% of U.S. children have a myopic condition. This number is rising with an increase in the proportion of children who wear reading glasses.

Subjects who used spectacle lenses with high add power had significantly improved quality of life when compared to subjects used with spectacle lenses with low add power, both with and without prescription for eyeglasses. When comparing high add power spectacle lenses to myopic refractive errors corrected myopia, there did not appear to be any difference in the objective outcomes of visual acuity nor in the subjective changes in eye discomfort, quality of life, or satisfaction in everyday activities when using lower add power spectacle lenses.

Data from a recent study the efficacy and tolerability of a novel spectacle lens was not confirmed. Data from a recent study of this preliminary study may suggest the need for further studies to investigate the safety and efficacy of this lenticulated spectacle in larger populations and/or with a longer duration.

The use of spectacle lenses with novel designs is becoming a more important feature of modern ophthalmology, even as this may have some risks. New lens designs must ensure comfort, optical performance and safety.

In a small number of patients, a new spectacle design is associated with a number of common side effects of the new spectacle, such as blurred vision (16·3%), red eyes (2·8%), photophobia (2·5%), irritation (1·9%) and itchiness (1·9%) in both patients with or without a history of previous spectacle wear. These side effects can be minimized by use of lower power non-permanent contact lenses. Inadequately selected patients with chronic eyes disease should be recommended to change the use to a non-permanent spectacle with lower power which can be used for longer and therefore reduce the number of side effects.